Consistently, CCNE overexpression is associated with poor clinical prognosis of bladder cancer, while inhibiting CCNE–CDK2 activity decreases cell proliferation and tumor formation and is deemed a therapeutic approach in human cancers [9–12]. The gene discussed is CDK2; the disease is neoplasm.